Zynerba Sketches Phase III Plan For Cannabinoid Gel In Fragile X
Executive Summary
Positive Phase II study of cannabinoid ZYN002 sends stock soaring, but the trial was very small with an open-label design, and response was mostly recorded by caregivers.
You may also be interested in...
Another Near Miss For Zynerba's Cannabidiol Gel
Zynerba's gel formulation of cannabidiol has failed to hit the primary endpoint in a second Phase II study in as many weeks, but the company maintains that there is a way forward.
Zynerba’s Cannabidiol Failure in Focal Seizures Not So Clear-Cut
Zynerba’s gel formulation of cannabidiol has disappointed in top-line data from a Phase II study in epilepsy patients with focal seizures, but some signals of efficacy in a companion study, and expected data from studies in two other indications, might influence future development plans.
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.